Data from 836 patients with implantable cardioverter defibrillator without or with cardiac resynchronization therapy enrolled in the Sensitivity of the InSync Sentry OptiVol feature for the prediction of Heart Failure ( SENSE-HF ) ( 1 ) study and the Diagnostic Outcome Trial in Heart Failure ( DOT-HF ) were pooled .